1. Abbott

2. Dr. Wallace C. Abbott
1888.
Begins manufacturing dosimetric granules
1894
Dr. Abbott acquires and becomes editor of The Alkaloidal Clinic
1900
Officially incorporated as the Abbott Alkaloidal Company
1906
To reach more physicians, Dr. Abbott establishes the
company’s sales force

3. History
• 1900 Modest Origin
• 1910 Expanded to
oNew York (US)
oSeattle (US)
oSan Fransico (US)
oToronto (Canada)
• 1915 changed name Abbott Laboratories
• 1929 about 120 facilities world wide
• Major player

4. Innovator Products
• Chlorazene 1916
• Butyn 1923
• Nembutal 1930
• Pantothal 1936
• Halazone 1942
• Tridione
• Surbex 1945
• Disposable I.V. Set
• Aminosol 1947
• Selsun Susp. 1951
• Erythrocin 1952
• Hytrin 1987

5. Acquisitions...
Year Acquisition Price Strategic Fit
2001 Knoll (a unit of BASF) $6.9B (Cash) Acquired the rights to
Humira
2004 Therasense $1.1B (Cash Acquired products for
diabetes treatment
2005 Guidant’s vascular
unit
$5.5B (Cash) Acquired several vascular
products
2006 Kos Pharmaceutical $3.7B (Cash) Acquired cholesterol
treatments
2009 Advanced Medical
Optics
$2.8B (Cash) Acquired #1 maker of LASIK
surgical devices
2009 Solvay’s drug unit $6.6B (Cash) Expanded pharmaceutical
portfolio
2010 Piramel Healthcare $3.8B (Cash) Expanded pharmaceutical
portfolio abroad

6. Business in 2011
• Record revenues of 38.9 Billions $
• 59 % of income came from outside US
Abbott Johnson &
Johonson
Pfizer Merk & co. Eli lilly &
Co.
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
30.00%
35.00%
Net Profit
Margin
ROE

7. Drug development cost in $
0
200
400
600
800
1000
1200
1400
1975 1987 2001 2006
Abbott
Abbott

8. • Oct 2011 Abbott plans to separate in two
companies
Abbott
Laboratories
Abbot Abb Vie

9. Idea of Global Citizenship
•Supporting patient and consumers
oEducating Patient and professionals
oEnsuring Manufacturing Quality
oResponsible sales and marketing
practices
•Safeguarding Environment
o Economic
oEnvironmental
oSocial Wellbeing
Scientific
Expertise
Business
Acumen
Recourses
Employees

10. Future Steps
• Research & Development
o30 Compounds in development
o12 Nutritional products and Medical devices
• Partnering with
oAcademics
oGovernment
oPrivate companies
To Advance personalise medicine, to improve
healthcare technology and to fight neglected
tropical diseases

11. Products